Elan dumps Alkermes shares in 'orderly' race to the exit
This article was originally published in Scrip
Elan has raised $381 million through the sale of 76% of its shares in Alkermes. Elan acquired 31.9 million shares in the new Alkermes and was granted $500 million in cash when it merged its formulation and manufacturing business Elan Drug Technology (EDT) with Alkermes in September 2011 (scripintelligence.com, 19 July 2011). That deal was valued at about $1 billion at closing, implying that Elan has realised neither gain nor loss on its latest transaction.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.